Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Global Lung Cancer Genomic Testing Market Size Revenue Is Forecast to Grow $3.015 Billion Mark by 2030, Growing at a CAGR of 9.1%

Published

on

<!– Name:DistributionId Value:8807353 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:2791 –> <!– Name:CustomerId Value:1092386 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:970b7803-4762-47a0-b778-b6db755a3391 –>

Washington, DC, April 13, 2023 (GLOBE NEWSWIRE) — Zion Market Research has published a new research report titled “Lung Cancer Genomic Testing Market By Sample Type (Liquid Biopsy And Tissue Biopsy), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), And Fluorescence In Situ Hybridization), By Type (Services And Products), By End-User (Hospitals/Clinics, Research Organization, And Diagnostic Laboratories), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030” in its research database.

“According to the latest research study, the demand of global Lung Cancer Genomic Testing Market size & share in terms of revenue was valued at USD 1.381 billion in 2022 and it is expected to surpass around USD 3.015 billion mark by 2030, growing at a compound annual growth rate (CAGR) of approximately 9.1% during the forecast period 2023 to 2030.”

What is Lung Cancer Genomic Testing? How big is the Lung Cancer Genomic Testing Industry?

Report Overview:

The global lung cancer genomic testing market size was worth around USD 1.381 Billion in 2022 and is predicted to grow to around USD 3.015 Billion by 2030 with a compound annual growth rate (CAGR) of roughly 9.1% between 2023 and 2030.

The global lung cancer genomic testing industry refers to the various tests involved in genome testing of tumors that cause lung cancer. It revolves around the analysis of the Deoxyribonucleic acid (DNA) of these mutated cells which is further used in the identification of the cause behind the mutation that leads to tumor growth in patients. The global volume is dependent on different types of genomic testing methods including polymerase chain reaction (PCR), next-generation sequencing (NGS) along with various other accompanying diagnostic tools that can aid the selection of patients that are more likely to show a positive reaction to selected therapies. Various factors are expected to help the global industry register surging numbers with the awareness about the benefits of the testing process rising rapidly. However, there are going to be certain roadblocks that may not be favorable during the forecast period.

Get a Free Sample PDF of this Research Report for more Insights with a Table of Content, Research Methodology, and Graphs – https://www.zionmarketresearch.com/sample/lung-cancer-genomic-testing-market

(A free sample of this report is available upon request; please contact us for more information.)

Our Free Sample Report Consists of the Following:

  • Introduction, Overview, and in-depth industry analysis are all included in the 2023 updated report.
  • The COVID-19 Pandemic Outbreak Impact Analysis is included in the package
  • About 209+ Pages Research Report (Including Recent Research)
  • Provide detailed chapter-by-chapter guidance on Request
  • Updated Regional Analysis with Graphical Representation of Size, Share, and Trends for the Year 2023
  • Includes Tables and figures have been updated
  • The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis
  • Zion Market Research research methodology

(Please note that the sample of this report has been modified to include the COVID-19 impact study prior to delivery.)

Global Lung Cancer Genomic Testing Market: Growth Factors

The global lung cancer genomic testing market is projected to grow owing to increasing advancements and developments in genomic testing technology allowing the production of accurate and faster results which helps the medical community deliver better treatment. Furthermore, the increasing investments in research and development of new genomic techniques especially that of next-generation sequencing (NGS) along with other supportive architecture is projected to help increase the global sales volume. With the ongoing increment in investments, it has become possible to improve the accuracy and availability of the testing methods, which leads to greater confidence and subsequent adoption.

In addition to this, the increasing interest in the healthcare sector in delivering and using personalized treatment has also witnessed favorable responses from the patient’s end. Personalized treatment refers to the customization or tailoring of medical plans that revolve around the genetic profile of every patient. It is starkly different from generic treatment, which may not be as effective as customized versions since it targets the exact cause of disease depending on the immunity response of the patient. The global market may also expect higher revenue owing to the various initiatives undertaken by governments worldwide to encourage the adoption of genomic testing systems. There has been a steady growth in the recognition of the importance of testing measures, especially for cancer treatment.

However, the lung cancer genomic testing industry lacks significant support in terms of appropriate medical reimbursement. This is visible in some of the countries that either lack the necessary medical infrastructure or financial assistance which means that the patients have to bear the burden of high expenses associated with genome testing procedures. Furthermore, a certain degree of healthcare professionals lacks the knowledge base required to successfully execute and interpret the advanced method for treatment which acts as a barrier against growth.

Directly Purchase a copy of the report with TOC @ https://www.zionmarketresearch.com/buynow/su/lung-cancer-genomic-testing-market

Report Scope

Report Attribute Details
Market Size in 2022 USD 1.381 billion
Projected Market Size in 2030 USD 3.015 billion
CAGR Growth Rate 9.1% CAGR
Base Year 2022
Forecast Years 2023-2030
Key Market Players CD Genomics, Qiagen NV, Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Agilent Technologies, Inc., Illumina, Inc., Thermo Fischer Scientific, Inc., Abbott Laboratories, Inc., Quest Diagnostics, Inc., OncoDNA, Centogene N.V., Admera Health, CeGaT GmbH, OPKO Health, Inc., and F. Hoffmann-La Roche AG.
Key Segment By Sample Type, By Technology, By Type, By End-User, And By Region
Major Regions Covered North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa
Purchase Options Request customized purchase options to meet your research needs. Explore purchase options

Lung Cancer Genomic Testing Market: Segmentation Analysis

The global lung cancer genomic testing market is segmented based on sample type, technology, type, end-user, and region

Based on sample type, the global market is divided into liquid biopsy and tissue biopsy.

Based on technology, the global market divisions are next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization

  • In 2022, the global market witnessed the highest growth in polymerase chain reaction (PCR) technology
  • The testing method is more cost-effective as compared to the rest of the methods and has proven to be accurate in terms of results
  • The PCR-based method is highly sensitive to detecting changes in chromosomes or genes
  • In 2022, more than 14000 people were diagnosed with lung cancer in Australia

Based on type, the lung cancer genomic testing industry is segmented into services and products.

Based on end-user, the global market segments are hospitals/clinics, research organizations, and diagnostic laboratories

  • During the forecast period, research organizations may witness the highest growth in this segment
  • The increasing interest of the research community in analyzing the complete potential of genome testing methods could be the driving factor
  • The US government spends around USD 200 billion annually on cancer care

The global Lung Cancer Genomic Testing market is segmented as follows:

By Sample Type

By Technology

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence in Situ Hybridization

By Type

  • Services
  • Products

By End-User

  • Hospitals/Clinics
  • Research Organization
  • Diagnostic Laboratories

Browse the full “Lung Cancer Genomic Testing Market By Sample Type (Liquid Biopsy and Tissue Biopsy), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Fluorescence in Situ Hybridization), By Type (Services and Products), By End-User (Hospitals/Clinics, Research Organization, and Diagnostic Laboratories), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2023 – 2030”– Report at https://www.zionmarketresearch.com/report/lung-cancer-genomic-testing-market

Competitive Landscape

Some of the main competitors dominating the global Lung Cancer Genomic Testing market include – 

  • CD Genomics
  • Qiagen NV
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
  • Agilent Technologies Inc.
  • Illumina Inc.
  • Thermo Fischer Scientific Inc.
  • Abbott Laboratories Inc.
  • Quest Diagnostics Inc.
  • OncoDNA
  • Centogene N.V.
  • Admera Health
  • CeGaT GmbH
  • OPKO Health Inc.
  • F. Hoffmann-La Roche AG.

 Key Insights from Primary Research:

  • According to the analysis shared by our research forecaster, the Lung Cancer Genomic Testing market is likely to expand at a CAGR of around 9.1% during the forecast period (2023-2030).            
  • In terms of revenue, the Lung Cancer Genomic Testing market size was valued at around US$ 1.381 billion in 2022 and is projected to reach US$ 3.015 billion by 2030.
  • Based on sample type segmentation, the liquid biopsy was predicted to show maximum market share in the year 2022.
  • Based on type segmentation, services were the leading type in 2022.
  • On the basis of region, North America was the leading revenue generator in 2022.

Have Any Query? Ask Our Experts: https://www.zionmarketresearch.com/inquiry/lung-cancer-genomic-testing-market

Key questions answered in this report:

  • What is the market size and growth rate forecast for Lung Cancer Genomic Testing industry?
  • What are the main driving factors propelling the Lung Cancer Genomic Testing Market forward?
  • What are the leading companies in the Lung Cancer Genomic Testing Industry?
  • What segments does the Lung Cancer Genomic Testing Market cover?
  • How can I receive a free copy of the Lung Cancer Genomic Testing Market sample report and company profiles?

Key Offerings:

  • Market Size & Forecast by Revenue | 2023−2030
  • Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities
  • Market Segmentation – A detailed analysis By Sample Type, By Technology, By Type, By End-User, And By Region
  • Competitive Landscape – Top Key Vendors and Other Prominent Vendors

Request for Customization on this Report as per your requirements – https://www.zionmarketresearch.com/custom/7133

(We tailor your report to meet your specific research requirements. Inquire with our sales team about customising your report.)

Regional Analysis:

North America is anticipated to lead the global lung cancer genomic testing market owing to the already existing advanced medical and research infrastructure of the US. Furthermore, the region is witnessing a surge in interest and subsequent investments in exploring the regional industry as various private and government players are entering the segment. The increasing demand for personalized care further encouraged by the monetary strength of the patient group could be a major regional growth propelling factor. The growing developments in DNA sequencing in the Asia-Pacific market could help the region generate high revenue. Countries like China, India, Japan, and others are making significant contributions toward the field of life sciences and biology.

By Region

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • France
    • UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific
  • The Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Recent Developments

  • In May 2022, the Global Fund and Roche entered a partnership aiming at developing diagnosis-related infrastructure to support low and middle-income groups suffering from the medical condition
  • In June 2022, Tempus, a leading player in the artificial intelligence segment announced a collaboration with Eli Lilly and Company. The move will be directed toward providing higher access to genome testing amongst patients suffering from advanced stages of non-small cell lung cancer (NSCLC)

To know an additional revised 2023 list of market players, request a brochure of the report: https://www.zionmarketresearch.com/requestbrochure/lung-cancer-genomic-testing-market

FREQUENTLY ASKED QUESTIONS

  • What is lung cancer genomic testing?
  • Which key factors will influence lung cancer genomic testing market growth over 2023-2030?
  • What will be the value of the lung cancer genomic testing market during 2023-2030?
  • What will be the CAGR value of the lung cancer genomic testing market during 2023-2030?
  • Which region will contribute notably towards the lung cancer genomic testing market value?
  • Which are the major players leveraging the lung cancer genomic testing market growth?

Browse Other Related Research Reports from Zion Market Research:

Cancer Biomarkers Market By Biomarkers Type (Protein Biomarkers, Genetic Biomarkers And Other Cancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin’s Lymphoma, Kidney Cancer And Other Cancer Types), By Profiling Technologies (Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics And Cytogenetics), By Application (Diagnostics, Research & Development, Prognostics, Risk Assessment And Other Applications) And By Region – Global Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data And Forecasts 2022 – 2028: https://www.zionmarketresearch.com/report/cancer-biomarkers-market

Lung Cancer Therapeutics Market By Cancer Type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), By Treatment (Immunotherapy, Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), By Drug Class (Antimetabolites, Alkylating Agents, Mitotic Inhibitors, EGFR Inhibitors, Multikinase Inhibitors, and Others), By End-User (Hospitals, Homecare, Specialty Clinics, and Others), and By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Internet, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025: https://www.zionmarketresearch.com/report/lung-cancer-therapeutics-market

Lung Cancer Diagnostics Market: by Type (Non-small Cell Lung Cancer and Small Cell Lung Cancer) and Test (Biopsy, Imaging Test, Molecular Test, Sputum Cytology, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025: https://www.zionmarketresearch.com/report/lung-cancer-diagnostics-market

Cervical Cancer Diagnostic Test Market (Pap Smear Tests, Colposcopy, HPV Testing, Endocervical Curettage (ECC) And Others) For Hospitals, Laboratories And Other End-Users – Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends And Forecast, 2021 – 2028: https://www.zionmarketresearch.com/report/cervical-cancer-diagnostic-test-market

Breast Cancer Drugs Market by Drug Type (Hormone Therapy, Chemotherapy Drugs, Targeted Therapy Drugs, and Other Therapeutic Drugs): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025: https://www.zionmarketresearch.com/report/breast-cancer-drugs-market

Cancer Supportive Care Drugs Market: by Drug Class (Granulocyte-Colony Stimulating Factors (G-CSF), Erythropoietin-Stimulating Agents (ESA), Antiemetics, Bisphosphonates, Opioids, Non-Steroidal Anti-Inflammatory Drugs (NSAID), and Others), and by Cancer Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Cancers): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025: https://www.zionmarketresearch.com/report/cancer-supportive-care-drugs-market

Cancer Biopsy Market – By Product (Kits & Consumables And Instruments), By Type (Tissue Biopsies And Liquid Biopsies), And By Region- Global Industry Perspective, Comprehensive Analysis, And Forecast, 2021 – 2028: https://www.zionmarketresearch.com/report/cancer-biopsy-market

Lung Cancer Surgery Market By Type (Surgical Instruments, Monitoring & Visualizing Systems, And Endosurgical Equipment), By Procedure (Robotic Surgery, Thoracotomy, Lobectomy, Sleeve Resection, Endobronchial Surgery, Pneumonectomy, Percutaneous Surgery, Segmentectomy, And Minimally Invasive Surgeries), By Treatment (Hospitals, Clinics, Ambulatory Surgical Centers, And Research Laboratories): Global Industry Perspective, Comprehensive Analysis And Forecast, 2021 – 2028: https://www.zionmarketresearch.com/report/lung-cancer-surgery-market

Cancer Registry Software Market by Type (Integrated and Standalone), by Database (Public and Commercial), by Delivery (Cloud and On-Premises), by Application (Cancer Reporting, Product Outcome Evaluation, Clinical Studies, Patient Care Management, and Medical Research), and by End-User (Hospitals, Healthcare Providers, Research Centers, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025: https://www.zionmarketresearch.com/report/cancer-registry-software-market

Ovarian Cancer Market: by Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, and Primary Peritoneal Carcinoma), by Cancer Stage (Stage I, Stage II, Stage III, and Stage IV), by Diagnostics (Physical Examination, Biopsy, Blood Tests, Human Chorionic Gonadotropin (hCG) test, ultrasound, MRI, PET, and CT scans), and by Treatment (Chemotherapy, Targeted Therapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, and Surgery): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 – 2024: https://www.zionmarketresearch.com/report/ovarian-cancer-market

About Zion Market Research:

Zion Market Research is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Zion Market Research are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.

Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Follow Us on LinkedIn: https://www.linkedin.com/company/zion-market-research/

Follow Us on Twitter: https://twitter.com/zion_research

Follow Us on Facebook: https://www.facebook.com/zionmarketresearch

Follow Us on Pinterest: https://www.pinterest.com/zionmarketresearch/

Follow Us on YouTube: https://youtu.be/Y0Yfi7N8zSs

Contact Us:

Rushikesh Dorge

USA: +1 347 690-0211

United Kingdom: +44 2032 894158

Japan: +81 50 5806 9039

India: +91 7768 006 007

Web: https://www.zionmarketresearch.com/

Blog: https://zmrblog.com/

Still, Looking for More Information? OR Want Data for Inclusion in Magazine, Case Study, or Media?

Email Directly Here with Detail Information: [email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

US Air Force Awards ThroughPut.ai Direct-to-Phase-II Contract for Boeing, Lockheed Martin, and Sikorsky Mission Design Series to Accelerate Aircraft Readiness

Published

on

us-air-force-awards-throughput.ai-direct-to-phase-ii-contract-for-boeing,-lockheed-martin,-and-sikorsky-mission-design-series-to-accelerate-aircraft-readiness

Leveraging Data to Drive Maintenance-first actions that improve overall supply chain throughput across the DAF.
NEW YORK, May 28, 2024 /PRNewswire/ — ThroughPut.ai, the Supply Chain Decision Intelligence Pioneer, announces it has been selected by AFWERX for a (SBIR Direct-to-Phase II contract) in the amount of $1,248,627.00 focused on “AI-Powered Proactive Supply Chain Capabilities” to address the most pressing challenges in the Department of the Air Force (DAF). The Air Force Research Laboratory and AFWERX have partnered to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small business and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018 which expanded the range of innovations the DAF funded and now on April 17th, 2024, ThroughPut.ai will start its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America.

“ThroughPut.ai looks forward to supporting efforts to accelerate inventory flow across the United States Air Force,” said Ali Raza, CEO & Founder of ThroughPut.ai. “By driving inventory/materiel management changes at the maintenance endpoint first, supply chain improvements can then be amplified across the greater industrial base to create aircraft capacity.”
“The views expressed are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of Defense, or the U.S. government.”
About (ThroughPut.ai)
ThroughPut.ai is a Silicon Valley-based supply chain optimization & predictive replenishment company. The company’s software AI platform has the ability to identify location-, product-, and customer-based demand changes sooner in order to adjust order frequencies, vendor sources, and parts buffer levels at a global and local scale. ThroughPut’s platform was designed by Fortune 500 & technology executives with real-world experience managing demand & supply chain disruptions and war-zone logistics across the Middle East.
About AFRLThe Air Force Research Laboratory is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development, and integration of affordable warfighting technologies for our air, space and cyberspace force. With a workforce of more than 12,500 across nine technology areas and 40 other operations across the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit afresearchlab.com.
About AFWERXAs the innovation arm of the DAF and a directorate within the Air Force Research Laboratory, AFWERX brings cutting-edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX employs approximately 370 military, civilian and contractor personnel at five hubs and sites executing an annual $1.4 billion budget. Since 2019, AFWERX has executed over 6,100 new contracts worth more than $4 billion to strengthen the U.S. defense industrial base and drive faster technology transition to operational capability. For more information, visit: www.afwerx.com. 
Company Press Contact:Ali RazaCEO/[email protected] 

View original content:https://www.prnewswire.co.uk/news-releases/us-air-force-awards-throughputai-direct-to-phase-ii-contract-for-boeing-lockheed-martin-and-sikorsky-mission-design-series-to-accelerate-aircraft-readiness-302156930.html

Continue Reading

Artificial Intelligence

Data Center Investments Soar: 200% Rise Since 2016 and Projected 89% Increase by 2028

Published

on

data-center-investments-soar:-200%-rise-since-2016-and-projected-89%-increase-by-2028

USA News Group CommentaryIssued on behalf of Avant Technologies Inc.
VANCOUVER, BC, May 28, 2024 /PRNewswire/ — Since 2016, investment in data centre infrastructure has risen 200%, with a further 89% increase expected by 2028 as more opportunities emerge with the rise of artificial intelligence (AI). According to Jones Lang LaSalle Inc.’s CEO Christian Ulbrich, data centers are “the hottest asset class at the moment.” Analysts at Technavio are projecting the global data center market to record an additional US$329.82 billion in growth at a CAGR of 12.73% through 2027. Capitalizing on the opportunity are several players recently announcing developments regarding their involvement in the data centers sector, including

Avant Technologies Inc. (OTCQB: AVAI), Amazon.com, Inc. (NASDAQ: AMZN), Applied Digital Corporation (NASDAQ: APLD), Digital Realty Trust, Inc. (NYSE: DLR), and Equinix, Inc. (NASDAQ: EQIX).
As an early pioneer in generative AI, Avant Technologies Inc. (OTCQB: AVAI) continues to enhance its flagship asset, Avant AITM, a sophisticated machine and deep learning AI system designed for versatility and customization across various industries and applications. Recently, Avant announced plans to equip its AI-managed data center, currently in development, with High-Performance Computing (HPC) systems. According to IBM, HPC technology utilizes clusters of powerful processors working in parallel to process massive multi-dimensional data sets and solve complex problems at exceptionally high speeds.
“The rise of AI is revolutionizing industries, and Avant Technologies is committed to being at the forefront of this transformation,” said William Hisey, CEO of Avant. “By building an AI-managed data center with HPC systems, we will gain the computational power and infrastructure required to train and deploy sophisticated AI models, which will ultimately provide even greater value to our customers.”
The new data center will leverage AI-driven management technology to optimize resource allocation and enhance efficiency in all aspects of data center operations. Avant will meticulously design its HPC infrastructure to meet the demands of AI workloads, selecting high-performance CPUs and GPUs (or TPUs) specifically suited for deep learning tasks. This cutting-edge facility will enable Avant to accelerate AI advancements, delivering innovative solutions to clients by improving data center efficiency and empowering them with exceptional AI capabilities.
Additionally, Avant will implement a high-speed network to ensure efficient data transfer and select a scalable storage solution to manage the large datasets necessary for training and utilizing AI models. The HPC systems will prioritize security, incorporating robust measures to protect sensitive data and create a secure environment for AI deployment. Furthermore, the data center will integrate energy-efficient technologies and sustainable design practices, reflecting Avant’s commitment to environmental responsibility.
Avant Technologies also recently announced plans to implement AI-empowered Zero Trust Architecture (ZTA) across its data center operations. Additionally, the company has expanded its AvantAI™ platform to include intelligent, proactive monitoring and management for data centers.
Over the past few weeks Amazon.com, Inc. (NASDAQ: AMZN) has collectively committed to investing $20 billion into new data centers for its subsidiary Amazon Web Services (AWS). The first to be announced was an $11-billion data center to be built in Indiana, with another $9 billion set to accelerate cloud-infrastructure in Singapore. The moves fall in line with Amazon CEO Andy Jassy’s projection that 85% of IT spending will remain on premises, in the race for Gen AI supremacy.
Amazon also recently announced an extension on its partnership between AWS and CrowdStrike to unify cybersecurity protection on its CrowdStrike Falcon platform. As per the agreement, Amazon is replacing a variety of cloud point products with Falcon Cloud Security, is using Falcon Next-Gen SIEM to secure big data logging and is deploying Identity Threat Detection and Response to prevent identity-based attacks.
“CrowdStrike and AWS have a deep history of working together to secure the most innovative companies in the world,” said CJ Moses, Chief Information Security Officer and Vice President of Security Engineering at Amazon. “Amazon uses CrowdStrike to provide visibility, detection, and response across our businesses in order to protect the cloud, infrastructure, and services for our customers. This is part of our shared mission to help all organizations build, operate, and secure their business.”
In a move to shore-up its market position as a designer, builder, and operator of next-generation digital infrastructure designed for High-Performance Computing (“HPC”) applications, Applied Digital Corporation (NASDAQ: APLD) recently announced the appointment of industry veteran Todd Gale as its new Chief Development Officer. The announcement came just one month after the company announced it had issued a $50 million unsecured convertible debenture to advance its HPC Data Center Project in Ellendale, North Dakota.
“We intend to use the net proceeds from the private financing, supplemented by the proceeds from our announced sale of the Garden City facility, to finance substantial advancements in our construction phase of the HPC data center in Ellendale, North Dakota,” said David Rench, CFO of Applied Digital. “Concurrently, we continue negotiating our project-level financing to ensure timely project completion and fulfillment of our contractual obligations.”
Applied Digital intends to utilize chipmaking giant NVIDIA’s new Blackwell platform into its cloud offerings. The company’s next-generation data center campuses are specifically designed to host HPC/AI applications, offering more cost-effective and efficient alternatives to traditional data centers.
In Japan, Digital Realty Trust, Inc. (NYSE: DLR) recently announced the expansion of its NRT Campus, by commencing construction of its third data center to support AI. Upon completion of the site in late 2025, the campus’s capacity will rise to 104MW, with the intention of meeting rising demand for next-generation infrastructure, and seamless access to Japan’s connected data communities.
“Japan’s rapidly increasing demand for AI deployments creates the need for scalable, flexible, and highly connected AI-ready data centers in the Tokyo metropolitan area,” said Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty. “We believe NRT14’s next-generation data center infrastructure and Digital Realty’s connected global open data center platform provide the foundational pillars our customers need to drive innovation in the coming years.”
Equinix, Inc. (NASDAQ: EQIX), another digital infrastructure company, has recently launched a $600 million joint venture with PGIM Real Estate to develop and operate the first xScale data center in the US, situated in California’s Silicon Valley. This follows their successful collaboration on the first xScale data center in Australia in 2022, which was part of a similar $575 million joint venture announced in 2021.
Under the terms of the new agreement, PGIM Real Estate will hold an 80% equity interest in the joint venture, while Equinix will retain a 20% equity stake. xScale data centers by Equinix enable hyperscale companies to expand their core deployments within Equinix’s IBX data centers, facilitating growth in over 70 global metros through a platform that supports direct interconnections with more than 10,000 customers.
This joint venture complements Equinix’s existing hyperscale collaborations in Europe, Asia-Pacific, and the Americas, significantly enhancing the global xScale data center portfolio. Once completed, this global expansion is set to exceed $8 billion, encompassing more than 35 facilities and providing over 725 megawatts of power capacity.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 
CONTACT:USA NEWS [email protected](604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/data-center-investments-soar-200-rise-since-2016-and-projected-89-increase-by-2028-302156928.html

Continue Reading

Artificial Intelligence

Lucinity Wins the Microsoft Partner Awards for 2024 for Partner of the Year – Iceland and Sustainability and Social Impact

Published

on

lucinity-wins-the-microsoft-partner-awards-for-2024-for-partner-of-the-year-–-iceland-and-sustainability-and-social-impact

REYKJAVÍK, Iceland, May 28, 2024 /PRNewswire/ — Lucinity, a leading AI company for financial crime prevention, won two awards at the Microsoft Partner Awards for 2024, including Partner of the Year – Iceland and Sustainability and Social Impact, highlighting Lucinity’s innovations and contribution to positive societal change. 

“Congratulations to Lucinity for being recognized as the Partner of the Year – Iceland 2024! Lucinity is leading digital transformation and delivering innovative products in their domain,” says Microsoft’s leadership.
“For the past year, they have played a key role with their offerings, skilled resources, and their ability to drive change and innovative solutions both locally in Iceland and across the globe. Lucinity has had significant social impact and growth while supporting our joint customers in their AI-transformation journeys.”
In June 2023, Lucinity launched the world’s first copilot for FinCrime prevention powered by Microsoft Azure OpenAI called Luci. Luci stands out in the financial services industry with specialized skills for FinCrime prevention such as adverse media checks, case analysis, and SAR writing. 
Built on the robust and scalable Microsoft Azure platform, Lucinity offers customers a trusted SaaS product. Additionally, Lucinity’s presence on the Microsoft Azure Marketplace allows companies to leverage their Microsoft Azure credits to access the platform. 
The seamless integration with Microsoft’s Azure stack has enabled Lucinity to implement advanced AI capabilities, fostering rapid innovation and enabling banks and fintech companies to utilize AI securely and audibly. Furthermore, Luci significantly reduces investigation times from 2.5 hours to just 25 minutes, saving Tier 1 banks an estimated $25 million annually.
Guðmundur Kristjánsson (GK), Lucinity’s Founder and CEO comments, “These awards are a testament to the strength and reliability of our solutions, made possible by our strategic partnership with Microsoft. Utilizing Microsoft Azure, we have been able to drive rapid innovation and create a robust, scalable platform that meets the rigorous requirements of compliance teams.” 
On the Sustainability and Social Impact Partner Award, Microsoft says, “Lucinity, with their innovative AI solutions, has really tried to combat this huge global challenge. They use ‘Human AI’ to enhance financial crime prevention, combining AI with human expertise for efficient, user-friendly solutions. Additionally, Lucinity has developed a tool called Luci, an AI-powered copilot that helps transform financial crime prevention from a process that took hours to one that takes minutes.”
Logo: https://mma.prnewswire.com/media/2208676/4669079/Lucinity_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/lucinity-wins-the-microsoft-partner-awards-for-2024-for-partner-of-the-year—iceland-and-sustainability-and-social-impact-302156888.html

Continue Reading

Trending